Staphylococcus Aureus Network Adaptive Platform Trial
ConditionStaphylococcus Aureus Bacteremia
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUniversity of Melbourne
About this trial
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
Eligibility criteria
Qualifiers
Staphylococcus aureus complex grown from ≥1 blood culture
Admitted to a participating hospital at the time of eligibility assessment (OR if patient has died, they were admitted to this site anytime from the time of blood culture collection until the time of eligibility assessment)
Disqualifiers
Time of anticipated platform entry is greater than 72 hours post collection of the index blood culture (Where the time of culture collection is not recorded, the time of laboratory registration of the sample will be used as an alternative)
Polymicrobial bacteraemia, defined as more than one organism (at species level) in the index blood cultures OR in any subsequent blood culture reported between the collection of the index blood culture and platform eligibility assessment, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician.
Known previous participation in the randomised SNAP platform
Known positive blood culture for S. aureus (of the same silo: PSSA, MSSA or MRSA) between 72 hours and 180 days prior to the time of eligibility assessment
Trial design
Treatments tested in this trial
- Cefazolin
- Penicillin
- Clindamycin
- Vancomycin
- Effectiveness of early switch to oral antibiotics
- Whole body FDG PET/CT Imaging
Treatment groups
8,000 Participants
are divided into 12 treatment groups12
Treatment groupsSee each treatment group below.
Sponsors and collaborators
University of Melbourne
Lead sponsor
Berry Consultants
Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborator
Menzies School of Health Research
Collaborator
Aotearoa Clinical Trials
Collaborator
Queensland University of Technology
Collaborator
Sunnybrook Health Sciences Centre
Collaborator
Tan Tock Seng Hospital
Collaborator
Telethon Kids Institute
Collaborator
The Peter Doherty Institute for Infection and Immunity
Collaborator
The University of Queensland
Collaborator
UMC Utrecht
Collaborator
Radboud University Medical Center
Collaborator
King's College London
Collaborator
Rambam Health Care Campus
Collaborator
University College, London
Collaborator
The Methodist Hospital Research Institute
Collaborator
Source ClinicalTrials.gov